Emerging Treatment Approaches and Multidisciplinary Management of Unresectable Stage III Non-Small Cell Lung Cancer - Episode 9
A 76-Year-Old Woman With Locally Advanced Unresectable Stage III EGFRm NSCLC
A 76-year-old woman with EGFR exon 19–positive adenocarcinoma and N3 disease undergoes chemoradiotherapy followed by osimertinib after a multidisciplinary evaluation and biomarker testing.
Video content above is prompted by the following:
- Briefly provide comments and perspectives on this patient case.
- How may your treatment approach differ for the patient in case 2 if they had presented with an ALK vs EGFR alteration?
- Prior to this year, what was your approach in patients with unresectable stage III disease if biomarker testing resulted as positive for EGFR mutation (EGFRm)?
Related Content:
